Application of ã-Cyclodextrin in Nanomedicinal Foods and Cosmetics

Bio-Nanotechnology: A Revolution in Food, Biomedical and Health Sciences

Volumn , Issue , 2013, Pages 179-211

  Uekaji, Yukiko ^a   Jo, Ayako ^a   Urano, Akihito ^a   Terao, Keiji ^a  

^a CycloChem Co Ltd   (Japan)

Author keywords

cyclodextrin; Absorption; Bioavailability; Complex; Cosmeceutical; Dipotassium glycyrrhizate; Micelle; Nanotechnology; Nutraceutical; Sodium taurocholate

Indexed keywords

EID: 84887139520     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118451915.ch10     Document Type: Chapter

References (54)

1. J. Szejtli, Cyclodextrins in food, cosmetics and toiletries, Starch/Stärke, 34 (11), 379-385 (1982).
2. G. Schmid, O.S. Huber, H.J. Eberle, Selective complexing agents for the production of γ-cyclodextrin, Proceedings of the 4th International Cyclodextrin Symposium, 87-92 (1988).
3. J. Szejtli, Dimethyl-β-cyclodextrin as parenteral drug carrier, Journal of Inclusion Phenomena, 1 (2), 135-150 (1983).
4. J. Szejtli, Highly soluble β-cyclodextrin derivatives, Starch/Stärke, 36 (12), 429-432 (1984).
5. C. Klein, G.E. Schulz, Structure of cyclodextrin glycosyltransferase refined at 2.0A resolution, Journal of Molecular Biology, 217 (4), 737-750 (1991).
6. K.E.B. Knudsen, Effect of dietary non-digestible carbohydrates on the rate of SCFA delivery to peripheral tissues, Foods and Food Ingredients Journal of Japan, 210 (11), 1008-1017 (2005).
7. M.T. Monforte, A. Trovato, S. Kirjavainen, A.M. Forestieri, E.M. Galati, R.B. Lo Curto, Biological effects of hesperidin, a citrus flavonoid. (Note II): Hypolipidemic activity on experimental hypercholesterolemia in rat, Farmaco, 50 (9), 595-599 (1995).
8. K. Ohtsuki, A. Abe, H. Mitsuzumi, M. Kondo, K. Uemura, Y. Iwasaki, Y. Kondo, Glucosyl hesperidin improves serum cholesterol composition and inhibits hypertrophy in vasculature, Journal of Nutritional Science and Vitaminology, 49 (6), 447-450 (2003).
9. K. Terao, D. Nakata, H. Fukumi, G. Schmid, H. Arima, F. Hirayama, K. Uekama, Enhancement of oral bioavailability of coenzyme Q10 by complexation with γ-cyclodextrin in healthy adults, Nutrition Research, 26, 503-508 (2006).
10. X. Gao, K. Nishimura, F. Hirayama, H. Arima, K. Uekama, G. Schmid, K. Terao, D. Nakata, H. Fukumi, Enhanced dissolution and oral bioavailability of coenzyme Q10 in dogs obtained by inclusion complexation with γ-cyclodextrin, Asian Journal of Pharmaceutical Sciences, 1 (2), 95-102 (2006).
11. S. Miyamoto, A. Kawai, S. Higuchi, Y. Nishi, T. Tanimoto, Y. Uekaji, D. Nakata, H. Fukumi, K. Terao, Structural studies of coenzyme Q10 inclusion complex with γ-cyclodextrin using chemical analy-sis and molecular modeling, Chem-Bio Informatics Journal, 9, 1-11 (2009).
12. V.R. Yadav, S. Suresh, K. Devi, S. Yadav, Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model, AAPS PharmSciTech, 10 (3), 752-762 (2009).
13. M.A. Tomren, M. Másson, T. Loftsson, H.H. Tønnesen, Studies on curcumin and curcuminoids. XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin, International Journal of Pharmaceutics, 338 (1-2), 27-34 (2007).
14. S. Ikeda, T. Uchida, T. Ichikawa, T. Watanabe, Y. Uekaji, D. Nakata, K. Terao, T. Yano, Complexation of tocotrienol with γ-cyclodextrin enhances intestinal absorption of tocotrienol in rats, Bioscience, Biotechnology, and Biochemistry, 74 (7), 1452-1457 (2010).
15. Y. Horiuchi, M. Kikuchi, F. Hirayama, K. Uekama, M. Ueno, T. Ijitsu, Improvement of bioavailability of menaquinone-4 by dimethyl-β-cyclodextrin complexation following oral administration, Yakugaku Zasshi, 108 (11), 1093-1100 (1988).
16. H. Reuscher, D.I. Kagan, D.L. Madhavi, Coated carotenoid cyclodextrin complexes, US Patent 109,920 (2004).
17. D. Nakada, K. Terao, M. Sato, T. Okamura, M. Tomita, Astaxanthin-cyclodextrin inclusion compound, Patent JP2008-291150 (2008).
18. K. Nukui, T. Yamagishi, H. Miyawaki, A. Kettawan, T. Okamoto, K. Sato, Comparison of uptake between PureSorb-QTM40 and regular hydrophobic coenzyme Q10 in rats and humans after single oral intake, Journal of Nutritional Science and Vitaminology, 53, 187-190 (2007).
19. I. Yamamoto, The whole story of a stable vitamin C derivative (AA-2G), Folia Pharmacologica Japonica, 132 (3), 160-165 (2008).
20. Y. Uekaji, A. Jo, M. Ohnishi, D. Nakata, K. Terao, A new generation of nutra-ceuticals and cosme-ceuticals complexing lipophilic bioactives with γ-cyclodextrin, Transactions of the Materials Research Society of Japan, 37, 89-94 (2012).
21. M.M. Fir, L. Milivojević, M. Prošek, A. Šmidovnik, Property studies of coenzyme Q 10-cyclodextrins complexes, Acta Chimica Slovenica, 56, 885-891 (2009).
22. P.R. Cabrer, E. Álvarez-Parrilla, W. Al-Soufi, F. Meijide, E.R. Núñez, J.V. Tato, Complexation of bile salts by natural cyclodextrins, Supramolecular Chemistry, 15 (1) 33-43 (2003).
23. M. Koid, R. Ishii, J. Ukawa, W. Tagaki, S. Tamagaki, Structural features of inclusion complexes between glycyrrhizinates and cyclodextrins, Journal of the Chemical Society of Japan, 7, 489-496 (1997).
24. D. Harries, D.C. Rau, V.A. Parsegian, Solutes probe hydration in specific association of cyclodextrin and adamantine, Journal of the American Chemical Society, 127, 2184-2190 (2005).
25. H. Takahashi, Y. Bungo, K. Mikuni, H. Beppu, S. Ozaki, K. Shimpo, Y. Itani, S. Sonoda, Improved thermal property and absorption of coenzyme Q10 in humans using cyclodextrin, Journal of Applied Glycoscience, 57 (3), 193-197 (2010).
26. H. Reuscher, CAVAMAX® W8 Curcumin. Technical Brochure of Wacker Chemical Corporation (Adrian, MI).
27. E.A. Serbinova, L. Packer, Antioxidant properties of α-tocopherol and α-tocotrienol, Methods in Enzymology, 234, 354-366 (1994).
28. S. Schaffer, W.E. Müeller, G.P. Echert, Tocotrienols: constitutional effects in aging and disease, Journal of Nutrition, 135 (2), 151-154 (2005).
29. T. Miyazawa, A. Shibata, P. Sookwong, Y. Kawakami, T. Eitsuka, A. Asai, S. Oikawa, K. Nakagawa, Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol), Journal of Nutritional Biochemistry, 20 (2), 79-86 (2009).
30. A.A. Qureshi, W.A. Salser, R. Parmar, E.E. Emeson, Novel tocotrienols of rice bran inhibit atherosclerotic lesions in C57BL/6 ApoE-deficient mice, Journal of Nutrition, 131 (10), 2606-2618 (2001).
31. S. Khanna, N.L. Parinandi, S.R. Kotha, S. Roy, C. Rink, D. Bibus, C.K. Sen, Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection, Journal of Neurochemistry, 112 (5), 1249-1260 (2010).
32. S. Ikeda, K. Toyoshima, K. Yamashita, Dietary sesame seeds elevate alpha-and gamma-tocotrienol concentrations in skin and adipose tissue of rats fed the tocotrienol-rich fraction extracted from palm oil, Journal of Nutrition, 131 (11), 2892-2897 (2001).
33. T. Ueda, O. Igarashi, New solvent system for ex-traction of tocopherols from biological specimens for HPLC determination and the evaluation of 2,2,5,7,8-pentamethyl-6-chromanol as an internal standard, Journal of Micronutrient Analysis, 3, 185-198 (1987).
34. N. Ukai, H. Nakamura, Y. Lu, H. Etoh, K. Ina, S. Ohshima, F. Ojima, H. Sakamoto, Y. Ishiguro, The water-solubilization and stabilization of lycopene by cyclodextrin and addition of protein, Nippon Shokuhin Kagaku Kogaku Kaishi, 43 (3), 247-250 (1996).
35. K. Uekama, T. Fujinaga, F. Hirayama, M. Otagiri, Y. Kurono, K. Ikeda, Effect of cyclodextrins on the acid hydrolysis of digoxin, Journal of Pharmacy and Pharmacology, 34 (10), 627-630 (1982).
36. K. Uekama, T. Fujinaga, M. Otagiri, H. Seo, M. Tsuruoka, Enhanced bioavailability of digoxin by γ-cyclodextrin complexation, Journal of Pharmacobio-Dynamics, 4 (9), 735-737 (1981).
37. K. Uekama, T. Fujinaga, F. Hirayama, M. Otagiri, M. Yamasaki, H. Seo, T. Hashimoto, M. Tsuruoka, Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation, Journal of Pharmaceutical Sciences, 72 (11), 1338-1341 (1983).
38. H. Seo, M. Tsuruoka, T. Hashimoto, T. Fujinaga, M. Otagiri, K. Uekama, Enhancement of oral bioavailability of spironolactone by β-and γ-cyclodextrin complexations, Chemical and Pharmaceutical Bulletin, 31 (1), 286-291 (1983).
39. K. Uekama, S. Narisawa, F. Hirayama, M. Otagiri, Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation, International Journal of Pharmaceutics, 16 (3), 327-338 (1983).
40. M. Katoh, F. Hamajima, T. Ogasawara, K. Hata, Assessment of human epidermal model LabCyte EPI-MODEL for in vitro skin irritation testing according to European Centre for the Validation of Alternative Methods (ECVAM)-validated protocol, Journal of Toxicological Sciences, 34 (3), 327-334 (2009).
41. H.N. Bhagavan, R.K. Chopra, N.E. Craft, C. Chitchumroonchokchai, M.L. Failla, Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model, International Journal of Pharmaceutics, 333 (1-2), 112-117 (2007).
42. U. Hoppe, J. Bergemann, W. Diembeck, J. Ennen, S. Gohla, I. Harris, J. Jacob, J. Kielholz, W. Mei, D. Pollet, D. Schachtschabel, G. Sauermann, V. Schreiner, F. Staeb, F. Steckel, Coenzyme Q10, a cutaneous antioxidant and energizer, BioFactors, 9, 371-378 (1999).
43. Institute of Medicine. National Academy of Sciences, Food and Nutrition Board, Panel on Dietary Antioxidants and Related Compounds, National Academy Press, Washington, DC (2000).
44. B.N. Ames, Endogenous oxidative DNA damage, aging, and cancer, Free Radical Research Communications, 7 (3-6), 121-128 (1989).
45. S. Loft, K. Vistisen, M. Ewertz, A. Tjonneland, K. Overvad, H.E. Poulsen, Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index, Carcinogenesis, 13 (12), 2241-2247 (1992).
46. H. Kasai, N. Iwamoto-Tanaka, T. Miyamoto, K. Kawanami, S. Kawanami, R. Kido, M. Ikeda, Life style and urinary 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage: effects of exercise, working conditions, meat intake, body mass index, and smoking, Japanese Journal of Cancer Research, 92 (1), 9-15 (2001).
47. S. Loft, H.E. Poulsen, Cancer risk and oxidative DNA damage in man, Journal of Molecular Medicine, 74 (6), 297-312 (1996).
48. M.S. Cooke, M.D. Evancs, K.E. Herbert, J. Lunec, Urinary 8-oxo-2 '-deoxyguanosine: source, signifi-cance and supplements, Free Radical Research, 32 (5), 381-397 (2000).
49. M. Kon, F. Kimura, T. Akimoto, K. Tanabe, Y. Murase, S. Ikemune, I. Kono, Effect of coenzyme Q10 supplementation on exercise-induced muscular injury of rats, Exercise Immunology Review, 13, 76-88 (2007).
50. J.E. Adams III, V.A. Miracle, Cardiac biomarkers: past, present, and future, American Journal of Critical Care, 7 (6), 418-423 (1998).
51. S. Narayanan, H.D. Appleton, Creatinine: a review, Clinical Chemistry, 26 (8), 1119-1126 (1980).
52. J. King, The dehydrogenases or oxidoreductases: lactate dehydrogenase. In: Practical Clinical Enzymology, J. King (Ed.).Van Nostrand: London, 83-93 (1965).
53. S. Okinaka, H. Kumagai, S. Ebashi, H. Sugita, H. Momoi, Y. Toyokura, Y. Fujie, Serum creatine phosphokinase: activity in progressive muscular dystrophy and neuromuscular diseases, Archives of Neurology, 4 (5), 520-525 (1961).
54. T. Minemura, Improved absorption of CoQ10 by fine particle design, Food Processing and Ingredients, 41 (3), 10-12 (2006).